PureTech Health PLC (PRTC) Peer Comparison

$17.38

$0.75 (4.51%)

As on 17-Jul-2026 09:30EDT

Market cap

$424 Mln

Revenue (TTM)

$-- Mln

P/E Ratio

--

P/B Ratio

1.2

Div. Yield

0 %

Edit

	PureTech Health PLC (PRTC)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Galapagos NV - ADR
Market cap ($ Mln)	424	2,928	2,262	2,152	1,862
Revenue ($ Mln)	5	450	120	549	1,044
Net Profit ($ Mln)	-109.74	-188.21	-57.50	17.88	488.78
Net Margin (%)	--	-41.86	-144.33	3.26	46.83
RoE (%)	-30.20	-28.46	-9.86	1.43	15.95
Price to Earnings	--	--	--	123.80	3.18
Price-To-Book	1.22	4.96	4.15	1.71	0.49

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	PureTech Health PLC (PRTC)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Galapagos NV - ADR
Operating Revenue	4.66	460.16	17.20	549.96	1,112.25
Cost of Revenue	3.36	191.08	5.13	337.24	29.74
Gross Profit	4.66	269.08	12.07	212.72	1,082.51
Operating Expenses	103.18	492.65	74.51	267.45	581.12
Operating Profit (EBIT)	-98.53	-223.57	-62.44	-54.73	501.39
Other Income	--	--	--	--	--
Profit before Tax	-110.93	-178.46	-101.81	522.72	300.87
Provision for Tax	-0.84	-2.93	0.33	63.78	-18.62
Profit after Tax (Net Income)	-109.74	-175.54	-102.14	458.12	320.88
Minority Interest	--	--	--	--	--
Consolidated Profit	--	--	--	--	--

Liabilities ($ Mln)

	PureTech Health PLC (PRTC)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Galapagos NV - ADR
Shareholder's Funds	312.07	715.50	597.44	1,237.93	3,234.49
Minority Interest	--	--	--	--	--
Non-Current Liabilities	182.73	40.72	84.62	186.06	17.78
Current Liabilities	46.31	416.17	102.63	315.78	152.80
Total Liabilities	534.71	1,172.38	784.68	1,753.10	3,405.07

Assets ($ Mln)

	PureTech Health PLC (PRTC)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Galapagos NV - ADR
Non-Current Assets	229.69	153.10	580.33	185.76	326.92
Current Assets	305.02	1,019.29	204.35	1,567.35	3,078.15
Total Assets	534.71	1,172.38	784.68	1,753.10	3,405.07
Total Debt*	19.59	224.26	128.16	97.89	6.92
Net Current Assets	258.71	603.12	101.72	1,251.57	2,926.59

Cashflow ($ Mln)

	PureTech Health PLC (PRTC)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Galapagos NV - ADR
Cash From Operating Activities	-85.33	-150.79	-49.95	-64.66	-189.23
Cash Flow from Investing Activities	63.44	307.87	0.12	-29.41	219.35
Cash from Financing Activities	-6.34	72.35	147.34	7.84	-3.14
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	PureTech Health PLC (PRTC)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Galapagos NV - ADR
ROCE (%)	-28.55	-18.15	-15.42	41.92	10.44
ROE (%)	-30.20	-22.56	-18.95	45.86	10.47
ROA (%)	-19.30	-14.89	-14.05	30.27	8.51
EBIT Margin (%)	--	--	--	--	--
Net Margin (%)	-2,355.42	-38.15	-593.92	83.30	28.85
Cash Profit Margin (%)	--	--	--	--	--

Growth Ratios

	PureTech Health PLC (PRTC)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Galapagos NV - ADR
Revenue Growth (%)	-0.04	0.15	1.91	-0.13	3.04
EBIT Growth (%)	--	--	--	--	--
Net Profit Growth (%)	-305.08	31.73	-16.13	1,114.23	333.15
EPS Growth (%)	-3.30	0.37	-0.02	11.14	3.39
Book Value Growth (%)	--	--	--	--	--

Valuation Ratios

	PureTech Health PLC (PRTC)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Galapagos NV - ADR
Price / Earnings	-3.64	-11.11	-13.58	5.08	6.71
Price / Book Value	1.28	2.73	2.32	1.88	0.67
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-2.27	-9.39	-18.38	-25.58	-2.33
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	PureTech Health PLC (PRTC)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Galapagos NV - ADR
Debt to Equity	0.06	0.31	0.21	0.08	0.00
Short term debt to equity ratio	0.03	0.29	0.10	0.02	0.00
Current Ratio	6.59	2.45	1.99	4.96	20.15
Quick Ratio	--	2.27	1.77	4.83	20.00
Interest Coverage	-1.42	-33.26	-3.49	-19.05	136.71

Operating Efficiency Ratios

	PureTech Health PLC (PRTC)	Zai Lab - ADR	Mesoblast - ADR	HUTCHMED (China) - ADR	Galapagos NV - ADR
Debtors to sales (%)	174.50	23.06	86.44	26.88	4.78
Asset Turnover	0.01	0.39	0.02	0.36	0.29
Receivable days	824.46	77.60	380.35	104.79	16.53
Inventory Days	--	109.55	791.94	49.57	452.54
Payable days	467.58	231.78	931.00	47.68	1,242.94
Cash Conversion Cycle	--	-44.63	241.30	106.67	-773.87

Annual
Quarterly